DR. MAYLI L DAVIS M.D.
Prescription History 1033192513
Ophthalmology - Ophthalmic Plastic and Reconstructive Surgery in Colleyville, TX

NPI Status: Active since November 29, 2005

Contact Information

6208 COLLEYVILLE BOULEVARD
SUITE 100
COLLEYVILLE, TX
ZIP 76034
Phone: (817) 329-4480
Fax: (817) 488-5993

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. MAYLI L DAVIS M.D., an active Ophthalmic Plastic and Reconstructive Surgery specialist practicing in Colleyville, TX. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 365 documented patient claims. Among these therapy options, the most frequently utilized medication is Erythromycin, which accounts for 162 claims alone.

Medication Index


Diazepam

Generic Formulation: DiazepamSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 40
TX State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills29.9
Peer Average Days Supply756
Conservative Utilization

This provider writes prescriptions for this formulation 37.0% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $15.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$0.89

State Avg Cost Per Claim

$7.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.

Therapeutic Applications

This medication is used to treat episodes of increased seizures (such as cluster or breakthrough seizures) in people who are already taking medications to control their seizures. This product is only recommended for short-term treatment of seizure attacks. It is not for ongoing daily use to prevent seizures. Uncontrolled seizures can turn into serious (possibly fatal) seizures that do not stop (status epilepticus). This medication is not recommended for children younger than 6 months of age because of the risk of serious side effects. Diazepam works by calming the brain and nerves. It belongs to a class of drugs known as benzodiazepines.

Erythromycin

Generic Formulation: Erythromycin BaseSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 162
30-Day Fills 162.0
Days Supply 1,874
TX State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills54.8
Peer Average Days Supply750
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 205.7% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,859.43 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.48

State Avg Cost Per Claim

$17.09

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Erythromycin is used to treat a wide variety of bacterial infections. It may also be used to prevent certain bacterial infections. Erythromycin is known as a macrolide antibiotic. It works by stopping the growth of bacteria. This antibiotic treats or prevents only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Methylprednisolone

Generic Formulation: MethylprednisoloneSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 29
30-Day Fills 29.0
Days Supply 189
TX State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills36.3
Peer Average Days Supply243
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $315.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.90

State Avg Cost Per Claim

$10.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A PREDNISOLONE derivative with similar anti-inflammatory action.

Therapeutic Applications

Methylprednisolone is used to treat conditions such as arthritis, blood disorders, severe allergic reactions, certain cancers, eye conditions, skin/kidney/intestinal/lung diseases, and immune system disorders. It decreases your immune system's response to various diseases to reduce symptoms such as swelling, pain, and allergic-type reactions. This medication is a corticosteroid hormone. Methylprednisolone may also be used with other medications in hormone disorders.

Neomycin-Polymyxin-Dexameth

Generic Formulation: Neomycin/Polymyxin B/DexamethaSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 33
30-Day Fills 33.2
Days Supply 360
TX State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills44.1
Peer Average Days Supply698
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $456.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.84

State Avg Cost Per Claim

$14.96

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat conditions involving swelling (inflammation) of the eyes and to treat or prevent bacterial eye infections. This product contains neomycin and polymyxin, antibiotics that work by stopping the growth of bacteria. It also contains dexamethasone, an anti-inflammatory corticosteroid that works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections and may worsen them (such as infections caused by viruses, fungi, mycobacteria). Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Restasis

Generic Formulation: CyclosporineSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 15
30-Day Fills 18.0
Days Supply 540
TX State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills91.0
Peer Average Days Supply2,702
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.6% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $12,060.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$804.05

State Avg Cost Per Claim

$1,152.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Tramadol Hcl

Generic Formulation: Tramadol HclSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 109
30-Day Fills 109.0
Days Supply 187
TX State Average Benchmarks
Peer Average Claims62.0
Peer Average 30-Day Fills63.6
Peer Average Days Supply1,282
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 75.8% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $146.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$1.34

State Avg Cost Per Claim

$7.68

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A narcotic analgesic proposed for severe pain. It may be habituating.

Therapeutic Applications

See also Warning section. This medication is used to help relieve moderate to moderately severe pain. Tramadol belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. MAYLI L DAVIS M.D. provides transparency into local medical care patterns within Colleyville, TX.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Ophthalmic Plastic and Reconstructive Surgery** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.